Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines

Hand, Foot and Mouth Disease Clinical Trial

Official title:

A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04111432
• Other study ID #: EV71-SN-2019-01
• Status: Completed
• Phase: Phase 4
• Start date: July 26, 2019
• Est. completion date: March 25, 2020

Study information

• Verified date: July 2021
• Source: Sinovac Biotech Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with measles mumps, and rubella combined live attenuated vaccine/ encephalitis live attenuated vaccine.

Description:

This study is an open-label, single-center, randomized, comparative phase IV clinical trial. The purpose of this study is to evaluate the safety andimmunogenicity of concomitant administration of EV71 vaccine manufactured by Sinovac (Beijing) Vaccine Technology Co., Ltd. with measles mumps, and rubella combined live attenuated vaccine/ encephalitis live attenuated vaccine. 360 healthy infants of 8 months old as participants are randomly assigned into three experimental groups in the ratio 1:1:1. The group I receive EV71 Vaccine (first dose)&measles mumps, and rubella combined live attenuated vaccine on day 0 and EV71 vaccine (second dose)&encephalitis live attenuated vaccine on day 30. The group II receive measles mumps, and rubella combined live attenuated vaccine on day 0 and encephalitis live attenuated vaccine on day 30. The group III receive the first and second dose of EV71 Vaccine on day 0 and day 30 respectively.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 372
• Est. completion date: March 25, 2020
• Est. primary completion date: November 25, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 8 Months and older

Eligibility

Inclusion Criteria:

• Healthy volunteer aged = 8 months;
• Proven legal identity;
• Guardians of the participants should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study.

Exclusion Criteria:

• Prior vaccination with EV71 vaccine;
• Prior vaccination with MMR vaccine or vaccine including mumps or measles or mumps or rubella vaccine components;
• Prior vaccination with Encephalitis B vaccine;
• Cannot be vaccinated with both arms at the same time;
• History of hand,foot and mouth disease;
• History of measles or mumps or rubella or encephalitis B;
• Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria,difficulty in breathing, angioneurotic edema, pain, etc;
• Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;
• Autoimmune diseases or immunodeficiency/immunosuppression;
• Severe neurological disorders (epilepsy, convulsions or convulsions) or psychosis;
• History of thyroidectomy, absence of spleen, functional absence of spleen, and any circumstances leading to absence of spleen or splenectomy;
• Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;
• Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) in the past 6 months;
• Receipt of any of the following products:

1. Blood product within 3 months prior to study entry;

2. Any live attenuated vaccine within 14 days prior to study entry;

3. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;

4. Any other study drugs within 30 days prior to study entry;

• Acute disease or acute stage of chronic disease within 7 days prior to study entry;
• Axillary temperature > 37.0#;
• Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.

Related Conditions & MeSH terms

• Hand, Foot and Mouth Disease
• Mouth Diseases

Intervention

Biological:
• Concomitant administration of EV71vaccine with EPI vaccines
The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.# the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
• Single injection of EPI vaccine
The MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
• EV71 Vaccine only
The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.

Locations

Country	Name	City	State
China	Hanbin District Center for Disease Control and Prevention	Ankang	Shaanxi

Sponsors (2)

Lead Sponsor	Collaborator
Sinovac Biotech Co., Ltd	Shaanxi Provincial Center for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The seroconversion rates(SCR) of the EV71 neutralizing antibody 30 days after two dose of EV71 vaccines	Immunogenicity indicator	30 days after two dose of EV71 vaccines
Secondary	The seroconversion rates(SCR) of the Measles IgG antibody,Rubella 30 IgG antibody and Mumps IgG antibody 60 days after one dose of MMR vaccine	Immunogenicity indicator	60 days after one dose of MMR vaccine
Secondary	The seroconversion rates(SCR) of the Japanese encephalitis neutralizing antibody 30 days after one dose of Encephalitis B vaccine	Immunogenicity indicator	30 days after one dose of Encephalitis B vaccine
Secondary	EV71 neutralizing antibody positive rate 30 days of two dose of EV71 vaccines	Immunogenicity indicator	30 days after two dose of EV71 vaccines
Secondary	The Geometric mean titer (GMT) of the EV71 neutralizing antibody 30 days of two dose of EV71 vaccines	Immunogenicity indicator	30 days after two dose of EV71 vaccines
Secondary	Measles IgG antibody,Rubella 30 IgG antibody and Mumps IgG antibody positive rate 60 days after one dose of MMR vaccine	Immunogenicity indicator	60 days after one dose of MMR vaccine
Secondary	The Geometric mean titer (GMT) of Measles IgG antibody,Rubella 30 IgG antibody and Mumps IgG antibody 60 days after one dose of MMR vaccine	Immunogenicity indicator	60 days after one dose of MMR vaccine
Secondary	The Japanese encephalitis neutralizing antibody positive rate 30 days after one dose of Encephalitis B vaccine	Immunogenicity indicator	30 days after one dose of Encephalitis B vaccine
Secondary	The Geometric mean titer (GMT) of Japanese encephalitis neutralizing antibody 30 days after one dose of Encephalitis B vaccine	Immunogenicity indicator	30 days after one dose of Encephalitis B vaccine
Secondary	Incidence of solicited local or systemic adverse events within 7 days or 14 days after each dose	Safety indicator	7 days or 14 days after each dose of injection
Secondary	The incidences of adverse reactions after each does	After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 or day 0-14 were reported. Unsolicited adverse events on day 0-30 were also reported.	0-30 days after each dose
Secondary	Incidence of serious adverse events (SAEs) during the period of safety monitoring	Serious adverse events (SAEs) will be collected during the period of safety monitoring after each dose	0-30 days after each dose